Income statement
CAD
Annual
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|
| Revenue | 27M | 689K | 13M | 0 | 280K |
| Gross Profit | 15M | 270K | 9M | 0 | 219K |
| Operating Income | -22M | -10M | -9M | -218K | -1M |
| EBITDA | -16M | -11M | -8M | -2M | -1M |
| Net Income | -14M | -9M | -11M | -218K | -1M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.0001
+0.00% today
1Y Change
+900.00%
Window
Jun 23, 2025 → Jun 17, 2026
Coverage: 248 bars · Jun 23, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Skylight Health Group Inc. (SLHGF) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 900.0% across the available one-year price window (Jun 23, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of +3841.5%, EPS growth of +32.7%, a dividend yield of 0.0%. What stands out right now is revenue +3841.5%, EPS +32.7%, free cash flow -357.8% with operating margin -75.3% and ROIC -25.9%. Valuation is more restrained than many high-expectation growth names at price/sales 0.0. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines SLHGF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SLHGF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SLHGF Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SLHGF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$280.1K
FY Net Income
-$1.3M
-475.8% YoY
Free Cash Flow
-$856.8
+99.1% YoY
Revenue Growth
+3841.5%
EPS Growth
+32.7%
Gross Margin
55.6%
Net Margin
-57.7%
Income statement
CAD
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|
| Revenue | 27M | 689K | 13M | 0 | 280K |
| Gross Profit | 15M | 270K | 9M | 0 | 219K |
| Operating Income | -22M | -10M | -9M | -218K | -1M |
| EBITDA | -16M | -11M | -8M | -2M | -1M |
| Net Income | -14M | -9M | -11M | -218K | -1M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
CAD
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|
| Cash & Equivalents | 12M | 20M | 130K | 28K | 1M |
| Total Assets | 65M | 31M | 9M | 84K | 9M |
| Total Liabilities | 27M | 4M | 8M | 120K | 4M |
| Shareholder Equity | 38M | 28M | 1M | -36K | 5M |
| Total Debt | 16M | 2M | 6M | 50K | 4M |
| Net Debt | 5M | -18M | 6M | 22K | 3M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
835
+99.1% YoY
Capital Expenditures
21
+91.1% YoY
Free Cash Flow
857
+99.1% YoY
Key ratios
Gross Margin
55.6%
Operating Margin
-75.3%
Net Margin
-57.7%
ROE
-47.8%
Debt / Equity
0.43x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.